Anthropic Adds Novartis CEO Vas Narasimhan to Its Board—Here’s Why That Matters

Anthropic just made a board appointment that tells you a lot about where the company sees itself heading. Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining the board through the company’s Long-Term Benefit Trust.

If you’re not familiar with that Trust, here’s the quick version: It’s an independent body whose members have zero financial stake in Anthropic. Its job is to keep the company honest—balancing the usual profit motives with the public benefit mission of developing AI for the long-term good of humanity. With Narasimhan’s appointment, Trust-appointed directors now make up a majority of the board. That’s not nothing.

Narasimhan isn’t your typical tech board hire. He’s spent his career in one of the most heavily regulated industries on the planet—pharma—overseeing the development and approval of more than 35 novel medicines. Daniela Amodei put it well: “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.”

That’s the kind of perspective that’s genuinely useful when you’re building something as consequential as frontier AI. Most board members come from finance, tech, or academia. Someone who’s navigated FDA approvals, global health crises, and the ethical tightrope of drug pricing? That’s a different skill set entirely.

Narasimhan’s background is worth noting. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and serves on the University of Chicago board of trustees. He also chaired the Pharmaceutical Research and Manufacturers of America. The guy has seen how technology can go wrong—and right—in high-stakes environments.

“Working across medicine, innovation, and global health has shown me the transformative potential of technology when deployed responsibly,” Narasimhan said in the announcement. He specifically cited AI accelerating solutions to hard scientific challenges, from understanding disease biology to designing better medicines.

This is higher than I expected from a standard board appointment announcement. Anthropic has been positioning itself as the “responsible AI” company since day one, but moves like this show they’re actually thinking about governance structure in a serious way. A Trust-appointed majority means the public benefit mission isn’t just a press release talking point—it’s baked into the corporate DNA.

Narasimhan joins a board that already includes Dario and Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. It’s a solid mix of tech founders, investors, and governance experts. Adding someone with deep healthcare and regulatory experience feels like a deliberate signal that Anthropic is thinking about real-world deployment, not just model capabilities.

The healthcare angle is particularly interesting. AI in medicine has been hyped for years, but actual deployment at scale has been slow—for good reason. Regulation, safety, and trust are massive barriers. Having someone who’s actually done the hard work of getting breakthrough treatments to patients globally could be invaluable as Anthropic pushes Claude into clinical settings.

I’m curious to see how this plays out. The Trust structure is unusual, and having a majority of directors appointed by a body with no financial stake creates an interesting dynamic. It’s not a perfect solution—there are always questions about who watches the watchers—but it’s a more thoughtful approach than most AI companies have taken.

For now, this is a solid hire. Narasimhan brings credibility, experience, and a track record of responsible innovation in a high-stakes field. If Anthropic is serious about AI safety and deployment, this is exactly the kind of perspective they need at the table.